29 results
8-K
EX-99.1
GH
Guardant Health Inc
24 May 24
FDA Advisory Committee Panel Strongly Recommends Approval of Shield™ Blood Test
7:01am
% in Every Community. https://nccrt.org/our-impact/80-in-every-community. Accessed May 21, 2024.
5. Raymond V, Foster G, Hong Y et al. Implementation
8-K
EX-99.1
GH
Guardant Health Inc
9 May 24
Guardant Health Reports First Quarter 2024 Financial Results and Increases 2024 Revenue Guidance
4:11pm
technology in scientific literature, demonstrating the impact our innovative suite of products have on both patients and the scientific community
8-K
EX-99.1
GH
Guardant Health Inc
22 Feb 24
Guardant Health Reports Fourth Quarter and Full Year 2023 Financial Results and Provides 2024 Outlook
4:10pm
for Shield™ demonstrating improved adherence with blood-based CRC screening
Collaborated with US Oncology Network and leading community oncology
8-K
EX-99.1
1yjag4
9 May 23
Guardant Health presents additional information from ECLIPSE study at 2023 Digestive Disease Week on the performance of Shield™ blood test
10:23am
8-K
EX-99.1
8mibid
15 Dec 22
Guardant Health announces positive results from pivotal ECLIPSE study evaluating a blood test for the detection of colorectal cancer
4:17pm
8-K
EX-99.1
01zr7f3606mf9yjcpon
23 Feb 22
Guardant Health Reports Fourth Quarter 2021 Financial Results and Provides 2022 Outlook
4:11pm
8-K
EX-99.1
5a8 ktri1
7 May 20
Guardant Health Reports First Quarter 2020 Financial Results
4:12pm
8-K
EX-99.1
5ze6l2e5
13 Jan 20
Regulation FD Disclosure
9:18am
424B4
ipo9 3n3ec805
24 May 19
Prospectus supplement with pricing info
4:01pm
DRS
l3ani
9 May 19
Draft registration statement
12:00am
DEF 14A
4djyepn1g dx1sfv6hbo
29 Apr 19
Definitive proxy
4:50pm